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PGS7
ISSUES IN USING CONJOINT ANALYSIS TO 
VALUE HEALTH CARE WITHIN
CLINICAL STUDIES
Girod I, Marquis P
Mapi Values, Lyon, France
INTRODUCTION AND OBJECTIVES: Recent applica-
tions of conjoint analysis (CA) in health care showed the
technique’s potential for measuring benefits beyond tra-
ditional health outcomes, particularly patient preferences
(PP). However, further methodological work is needed to
generalize its application into clinical research. This ab-
stract discusses the issues addressed during a recent PP
research in benign prostatic hyperplasia (BPH) patients.
METHODS: Issues were addressed at the different stages
of PP design: 1) identify attributes to include in the sce-
narios; 2) choose attribute levels; 3) select scenarios to
present; 4) decide which was the suitable method to elicit
patient preferences; and 5) choose the CA. RESULTS: 1-
Attributes were identified using patient interviews, litera-
ture review and drug profiles (side-effect, daily cost, time
to onset). The selection of the most important attributes
for patients addressed the question of defining their rele-
vance. Six attributes were selected in our study. 2- At-
tribute levels were determined to make trade-off possible
while remaining realistic. The margin between these two
concepts was narrow for the attributes chosen, for exam-
ple the daily cost of medical treatment ranged from $1 to
$1.5. 3- A fractional factorial design was employed to de-
termine the 16 scenarios that were administered to keep
the patient burden acceptable (less than 12 minutes). Three
sets of scenarios in different orders were administered, as
order may affect the results of CA. 4- The method for PP
elicitation was discussed in order to find a common de-
sign to assess quality of life, PP and clinical criteria
within the same study. Auto-administration methods were
preferred to interview-administration, to limit clinician
burden and because of the sample size: 871 patients. Rat-
ing methods were chosen as the simplest approach. 5-
Data were analyzed using ordered probit regression tech-
niques. CONCLUSION: When following theoretical and
methodological guidelines for assessing PP, researchers
need to take into account study design, the size of the
sample and the number of outcomes measured within the
same study.
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ECONOMIC ASSESSMENT OF THE DIRECT 
SPECIFIC COST OF BENIGN PROSTATIC 
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INSURANCE PERSPECTIVE
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2Pharmaco-Economic programs, Pierre Fabre Laboratories, 
Boulogne, France
OBJECTIVE: To investigate the monthly direct cost of
benign prostatic hyperplasia(BHP) from the health insur-
ance perspective and according to the management op-
tion: watchful waiting or medication. METHOD: 1.756
subjects with a non-complicated BHP diagnosed for over
3 months and without surgery antecedent have been in-
cluded between May and October 1999 by 316 general
practitioners. Two patient groups have been identified:
with medication (n  1561) or watchful waiting (n 
191). For each patient, the disease history and all specific
medical resources consumed during the last three months
have been collected: hospitalization, drugs, consultations
and lab tests. Clinical profile: Mean age: 67.7 years, Weight/
Length: 77.7 kg/171.6 cm, PAS/PAD: 138.4/79.1 mmHg,
BHP diagnostic: 3.5 years (/ 3.47), Score Interna-
tional-Prostate Symptom Score (I-PSS): 0 to 7 (mean
4.63): 28 %, 8 to 19(mean 12.82): 58%, 20 to 35(mean
23.87): 12% RESULTS: The total average specific direct
cost of care per month, calculated on all included pa-
tients was 26.2€ per patient: drug (39%), lab test (25%),
hospitalization (21%), consultations (15%). The break-
down of costs by severity shows that the disease progres-
sion induces higher cost: score I-PSS 0 to 7: 18.5€, score
I-PSS 8 to 19: 26.2€; score I-PSS 20 to 35: 47.3€. The eco-
nomic assessment shows a difference in favour of the
group with medication. (26€ versus 31.7€ per month).
CONCLUSION: The patients treated by BPH drug con-
stitute a lower financial burden for the Health Insurance
than patients without BPH drug. This difference, extrap-
olated to 68€ per year, is explained by the low reimburse-
ment rate (35%) of the BHP drug by the French Health
Insurance, and a best reimbursement rate of all other
resources used (hospitalization: 100%, consultations: 70%).
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THE IMPACT OF DEMENTIA ON THE QUALITY 
OF LIFE OF CAREGIVERS OF ELDERLY PEOPLE
Scuvée-Moreau J, Kurz X, Dresse A
Laboratory of Pharmacology, University of Liège, Liège, Belgium
OBJECTIVE: to assess the impact of dementia and its se-
verity on mental health, physical health and social func-
tioning of caregivers of elderly people living at home.
METHODS: Study population: 181 caregivers of subjects
aged 65 with mild (D1), moderate/mild (D2), moderate
(D3) or severe dementia (D4), 118 caregivers of non-de-
mented subjects aged 65 with (R2) or without (R1)
cognitive disorders. Generic quality of life (QOL) was as-
sessed with COOP/WONCA and SF-36 measures. De-
